Risk factors and outcome of Chimeric Antigen Receptor T-Cell patients admitted to Pediatric Intensive Care Unit: CART-PICU study

INTRODUCTION: Chimeric antigen receptor (CAR)T-cell CD19 therapy is an effective treatment for relapsed/refractory B-cell acute lymphoblastic leukemia. It can be associated with life-threatening toxicities which often require PICU admission. Purpose: to describe clinical characteristics, treatment a...

Descripción completa

Detalles Bibliográficos
Autores principales: Caballero-Bellón, Marina, Alonso-Saladrigues, Anna, Bobillo-Perez, Sara, Faura, Anna, Arqués, Laura, Rivera, Cristina, Català, Albert, Dapena, Jose Luis, Rives, Susana, Jordan, Iolanda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10433898/
https://www.ncbi.nlm.nih.gov/pubmed/37600775
http://dx.doi.org/10.3389/fimmu.2023.1219289

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10433898/
https://www.ncbi.nlm.nih.gov/pubmed/37600775
http://dx.doi.org/10.3389/fimmu.2023.1219289

Ejemplares similares